News
ADAG
2.060
-4.19%
-0.090
Are Medical Stocks Lagging Adagene (ADAG) This Year?
NASDAQ · 1d ago
Weekly Report: what happened at ADAG last week (1125-1129)?
Weekly Report · 5d ago
Weekly Report: what happened at ADAG last week (1118-1122)?
Weekly Report · 11/25 11:43
Weekly Report: what happened at ADAG last week (1111-1115)?
Weekly Report · 11/18 11:39
Adagene’s ADG126: Promising Efficacy Amid Regulatory Uncertainty Warrants Hold Rating
TipRanks · 11/15 19:05
Adagene downgraded to Hold from Buy at Jefferies
TipRanks · 11/15 18:55
Weekly Report: what happened at ADAG last week (1104-1108)?
Weekly Report · 11/11 11:56
Adagene Unveils Promising Data for Cancer Therapy
TipRanks · 11/07 15:28
Adagene presents data on ADG126 at SITC Annual Meeting
TipRanks · 11/07 15:25
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at
Barchart · 11/07 09:01
Weekly Report: what happened at ADAG last week (1028-1101)?
Weekly Report · 11/04 11:52
Weekly Report: what happened at ADAG last week (1021-1025)?
Weekly Report · 10/28 11:43
Weekly Report: what happened at ADAG last week (1014-1018)?
Weekly Report · 10/21 11:38
Weekly Report: what happened at ADAG last week (1007-1011)?
Weekly Report · 10/14 12:12
Weekly Report: what happened at ADAG last week (0930-1004)?
Weekly Report · 10/07 11:59
Weekly Report: what happened at ADAG last week (0923-0927)?
Weekly Report · 09/30 11:51
Weekly Report: what happened at ADAG last week (0916-0920)?
Weekly Report · 09/23 11:50
Adagene Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 09/18 14:11
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga · 09/18 14:00
Buy Rating Affirmed on Adagene: Promising ADG126 Clinical Data and Market Underappreciation
TipRanks · 09/18 12:55
More
Webull provides a variety of real-time ADAG stock news. You can receive the latest news about Adagene Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.